Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Pulmonary | 9 | 2023 | 324 | 1.390 |
Why?
|
| Mycobacterium tuberculosis | 8 | 2023 | 329 | 1.200 |
Why?
|
| Tuberculosis | 7 | 2025 | 543 | 0.930 |
Why?
|
| Antitubercular Agents | 9 | 2025 | 322 | 0.830 |
Why?
|
| Sputum | 4 | 2023 | 135 | 0.570 |
Why?
|
| HIV Infections | 11 | 2023 | 5097 | 0.550 |
Why?
|
| Rifampin | 3 | 2025 | 197 | 0.430 |
Why?
|
| Isoniazid | 4 | 2023 | 110 | 0.420 |
Why?
|
| Bacteriological Techniques | 2 | 2021 | 54 | 0.360 |
Why?
|
| HIV-1 | 4 | 2021 | 1260 | 0.320 |
Why?
|
| Humans | 19 | 2025 | 14537 | 0.280 |
Why?
|
| Adult | 12 | 2025 | 5913 | 0.260 |
Why?
|
| Bacterial Load | 2 | 2023 | 32 | 0.240 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.230 |
Why?
|
| Exhalation | 1 | 2023 | 3 | 0.220 |
Why?
|
| Bacillus | 1 | 2023 | 7 | 0.220 |
Why?
|
| Female | 12 | 2025 | 9103 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 146 | 0.210 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 91 | 0.210 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 47 | 0.180 |
Why?
|
| Biological Assay | 1 | 2020 | 32 | 0.180 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 45 | 0.180 |
Why?
|
| HLA Antigens | 1 | 2020 | 50 | 0.170 |
Why?
|
| Ethambutol | 1 | 2020 | 9 | 0.170 |
Why?
|
| Pyrazinamide | 1 | 2020 | 14 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2020 | 135 | 0.170 |
Why?
|
| Male | 8 | 2025 | 6754 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 195 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 132 | 0.160 |
Why?
|
| Receptors, IgG | 1 | 2019 | 28 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2020 | 167 | 0.160 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 265 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2025 | 279 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 529 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2018 | 97 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2021 | 1160 | 0.130 |
Why?
|
| Young Adult | 5 | 2021 | 2498 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2025 | 889 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 472 | 0.110 |
Why?
|
| Pregnancy | 4 | 2020 | 1862 | 0.110 |
Why?
|
| Middle Aged | 4 | 2025 | 3601 | 0.110 |
Why?
|
| South Africa | 6 | 2021 | 7596 | 0.110 |
Why?
|
| Comorbidity | 2 | 2021 | 188 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 370 | 0.080 |
Why?
|
| Infant | 3 | 2020 | 2244 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2021 | 656 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2021 | 480 | 0.080 |
Why?
|
| Adolescent | 3 | 2021 | 2985 | 0.080 |
Why?
|
| Aged | 2 | 2025 | 1740 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1422 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2020 | 1479 | 0.060 |
Why?
|
| Child | 2 | 2021 | 2242 | 0.060 |
Why?
|
| Firmicutes | 1 | 2023 | 7 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2023 | 3 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 10 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 15 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 39 | 0.050 |
Why?
|
| World Health Organization | 1 | 2023 | 137 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 244 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 4 | 0.050 |
Why?
|
| Microscopy | 1 | 2021 | 21 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 46 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2021 | 26 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Mycobacterium smegmatis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 156 | 0.050 |
Why?
|
| Tuberculin Test | 1 | 2020 | 49 | 0.040 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 1324 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 143 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 119 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2020 | 165 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 117 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 89 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 105 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 6 | 0.040 |
Why?
|
| Immunogenetic Phenomena | 1 | 2019 | 7 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 48 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2019 | 36 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 52 | 0.040 |
Why?
|
| Coinfection | 1 | 2021 | 276 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 685 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2018 | 35 | 0.040 |
Why?
|
| Zidovudine | 1 | 2018 | 59 | 0.040 |
Why?
|
| Gestational Age | 1 | 2018 | 80 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2019 | 175 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 819 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 56 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 1475 | 0.030 |
Why?
|
| Mothers | 1 | 2018 | 195 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 418 | 0.030 |
Why?
|